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Research Article
Multiplatform characterization of dynamic
changes in breast milk during lactation
The multicomponent analysis of human breast milk (BM) by metabolic profiling is a
new area of study applied to determining milk composition, and is capable of associ-
ating BM composition with maternal characteristics, and subsequent infant health out-
comes. A multiplatform approach combining HPLC-MS and ultra-performance LC-MS,
GC-MS, CE-MS, and 1H NMR spectroscopy was used to comprehensively characterize
metabolic profiles from seventy BM samples. A total of 710 metabolites spanning multi-
ple molecular classes were defined. The utility of the individual and combined analytical
platforms was explored in relation to numbers of metabolites identified, as well as the
reproducibility of the methods. The greatest number of metabolites was identified by the
single phase HPLC-MSmethod, while CE-MS uniquely profiled amino acids in detail and
NMR was the most reproducible, whereas GC-MS targeted volatile compounds and short
chain fatty acids. Dynamic changes in BM composition were characterized over the first
3 months of lactation. Metabolites identified as altering in abundance over lactation in-
cluded fucose, di- and triacylglycerols, and short chain fatty acids, known to be important
for infant immunological, neurological, and gastrointestinal development, as well as be-
ing an important source of energy. This extensive metabolic coverage of the dynamic BM
metabolome provides a baseline for investigating the impact of maternal characteristics,
as well as establishing the impact of environmental and dietary factors on the composition
of BM, with a focus on the downstream health consequences this may have for infants.
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 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Understanding breast milk (BM) composition and how it
changes over lactation is of importance in our continuing
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free induction decay; HMO, human milk oligosaccharides;
IS, internal standard; MFE, molecular feature extraction;
MTBE, methyl tert-butyl ether; OPLS-DA, orthogonal partial
least square discriminant analysis; PCA, principal compo-
nent analysis; PLS-DA, partial least square discriminant anal-
ysis; QC, quality control; SCFA, short chain fatty acids; TSP,
3-trimethylsilyl propionic acid; TMS, tetramethylsilane;
UPLC-MS, ultra-performance LC-MS
efforts to find the best way to feed babies when maternal
milk is unavailable, in terms of understanding how to ad-
vise mothers, and in designing human milk substitutes [1].
Breast milk is a complex biofluid; in addition to containing
nutrients for infant growth and development, many chemical
and biologically active factors are present whose purpose is
not to provide nutrition, but to promote healthy infant devel-
opment. For example, choline [2] and taurine [3] are essential
factors needed for neurodevelopment, contributing toward
membrane biosynthesis and neurotransmission.
Analysis of BM composition is complicated by many fac-
tors, including the changing nutritional composition of BM
over the course of a feed, throughout the day, in response
to maternal diet, as well as over the course of lactation [4].
Additionally, the presence of large macromolecules and the
ultrastructure of BM, which is micellar, mean analytical tech-
niques must be preceded by sample preparation methods to
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reduce the complexity of BMprior to analysis. To date, studies
on milk composition have primarily focused on macronutri-
ent content, investigating total fat, protein, and lactose, or on
analysis of a single component such as humanmilk oligosac-
charides (HMO) [5].
Here, we set out to apply metabonomic technologies,
including 1H NMR spectroscopy and MS coupled with GC,
HPLC, ultra-performance LC (UPLC), andCE, to characterize
themicronutrient composition of BMusing a sample volume
smaller than traditional analytical techniques allow [6].
Very little previous research using metabonomics to
analyze BM has been carried out. Only four studies using
1H NMR spectroscopy to profile global BM composition
were identified using a search in PubMed [7–10]. Previous
studies on BM composition using MS have predominantly
investigated the lipid content [11] or structures of HMO [5].
Recently, one study has combined some of these high
throughput techniques, HPLC-MS and GCMS, using a
single phase extraction to widen the global metabolite profile
obtainable from BM [12]. The reluctance to implement a
multiplatform approach in BM analysis may arise from the
fact that each analytical technique normally requires different
preprocessing steps, thus increasing the amount of sample
volume and preparation time required. We therefore aimed
to establish simple sample preparation protocols for the
preanalytical preparation of BM samples for multiplatform
metabonomic techniques, thus reducing the total volume
of milk and preparation time required for achieving a
comprehensive coverage of the milk metabolome.
Once the analytical protocol was established, we used
a set of 70 BM samples, collected from 57 mothers, to (i)
compare the relative sensitivity, and complementarity of the
various analytical platforms, (ii) describe the global metabolic
profile of BM and, (iii) ascertain the capability of these meth-
ods to explore the temporal change that occurs over the first
three months of lactation. LC-MS, GC-MS, and 1H NMR
spectroscopy were used to characterize hydrophobic metabo-
lites while polar metabolites were analyzed using 1H NMR
spectroscopy and CE-MS. To ensure reproducibility of the
extraction protocols and analytical procedures, evaluation of
analytical platforms was undertaken using metabolites cho-
sen to cover the full range of the spectral profiles for each
technique, taking into consideration the RSD.
2 Materials and methods
2.1 Samples
The studies which these samples were collected for were
approved by the UK National Research Ethics Service (ref
08/H07114/3 and 10/H0713/5). The mother’s written, in-
formed, consent was obtained. Seventy milk samples were
obtained from 57 mothers, who delivered healthy term-born
infants. Predominantly hindmilk (collected postfeed) sam-
ples were obtained between 2 and 80 days postbirth, by man-
ual expression. Samples were collected into collection bottles
and aliquoted into 1.5 mL microcentrifuge tubes. Samples
were frozen as soon as possible after collection and stored at
–80°C until analysis. Before analysis, samples were defrosted
at room temperature and vortexed vigorously to resuspend
the milk fat globules.
2.2 Sample pretreatment
2.2.1 Dual phase extraction
Amodified Folch extraction procedurewas employed in order
to prepare the samples for analysis [13]. Two milliliters of
chloroform/methanol in a 2:1 ratio was added to 400 L of
wholemilk. Thismixture was vortexed and 600L of purified
water was added. Samples were then centrifuged for 10 min
at 16 000 × g.
This method produces two phases and metabolites
split into the different phases according to their polarity.
Both phases were separated and evaporated to dryness
using a speed vacuum concentrator (Eppendorf, Hamburg,
Germany). Once dry, the phases were frozen at –80°C until
analysis.
2.2.2 Single phase extraction
A single phase extraction method previously published [12]
was also used to prepare BM samples for analysis using
HPLC-MS and GC-MS. This involved mixing 50 L of BM
with 350 L of methanol: methyl tert-butyl ether (MTBE) in a
1:1 ratio. This mixture was then vortexed for 1 min to precipi-
tate proteins. Vitamin E acetate was used as internal standard
(IS), at a concentration of 25 mg/L.
A flowchart describing the analysis of the different
fractions of BM using the different analytical platforms in
order to characterize as many BM metabolites as possible
is presented in Fig. 1. Sample preparation methods were
selected according to the idiosyncrasies of each of the ana-
lytical techniques used, as well as instrumental availability.
To optimize the HPLC-MS method, particularly with respect
to metabolite recovery, as we observed recovery of certain
metabolites to be split across the aqueous and organic phase
when using the dual phase extraction, we subsequently
evaluated the single phase extraction, which is capable of
extracting both moderately polar and apolar compounds si-
multaneously. Sampleswere analyzed in a single randomized
run to minimize batch effects for all analytical techniques.
2.3 1H NMR sample preparation
The aqueous and lipid extracts were prepared using the mod-
ified Folch technique described above from 63 BM samples.
The aqueous phase dried extract was reconstituted in 600 L
of D2O phosphate buffer, pH 7.2, with 3-trimethylsilyl pro-
pionic acid (TSP) as an IS. The organic phase dried extract
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Figure 1. Workflow display-
ing the different metabonomic
techniques selected to analyze
the aqueous and lipid fraction
of BM extractions.
was reconstituted in 600 L of deuterated chloroform with
tetramethylsilane (TMS) as an IS. The reconstituted phases
were transferred to 5 mm capillary tubes for 1H NMR spec-
troscopic analysis.
A quality control (QC) sample was prepared by pooling
50 L of each of the samples; this QC sample was aliquoted
and analyzed every ten samples.
2.4 CE-MS sample preparation
Twenty-one individual BM samples were prepared using the
modified Folch method outlined above. The dried aqueous
extract corresponding to 200 L of BM was resuspended in
200 L of 20 mM of formic acid solution and centrifuged
to remove any particulate matter. The supernatant was trans-
ferred to a vial ready for injection into the CE-MS instrument.
A QC sample was prepared by pooling 20 L of each of
the samples and an aliquot was analyzed every six samples.
2.5 UPLC-MS lipid fraction sample preparation
Twenty one individual BM samples were prepared using the
modified Folchmethod outlined above. The dried lipid extract
corresponding to 200 L of BM was resuspended in 200 L
of 2:1:1 isopropanol/water/acetonitrile (IPA:H2O:ACN), and
centrifuged to remove any particulate matter. The super-
natant was transferred to a vial, ready for injection into the
ultra-performance LC-MS (UPLC-MS) instrument.
Fifty microliters of each sample was also pooled and an-
alyzed as a QC sample every six samples.
2.6 HPLC-MS sample preparation
Thirty-six BM samples were prepared using the methanol-
MTBE single phase outlined above.
QC samples were obtained after pooling 50 L of each
sample that was analyzed at the beginning and at the end of
the sequence, and after every five samples to check system
stability and performance of the analysis.
2.7 GC-MS sample preparation
A single phase extraction was carried out on 200 L of 18
BM samples, as outlined above. As previously described an
aliquot of 150 L, taken from the supernatant of the ex-
traction, was transferred to a GC vial and evaporated to
dryness in a speed vacuum concentrator [14]. Methoxyma-
tion was carried out in the dark, at room temperature for
16 h after adding 10 L of O-methoxyamine hydrochlo-
ride in pyridine (15 mg/mL) to each GC vial, the resul-
tant mixture was vortexed for 5 min. For derivatization,
20 L of N,O-Bis(trimethylsilyl)trifluoroacetamide with 1%
trimethylchlorosilane was added to each sample and the so-
lution was vortexed again for 5 min. Silylation was achieved
after samples were heated in an oven for 1 h at 70°C. Finally,
100 L of IS, heptane containing 10 ppm of C18:0 methyl es-
ter, was added to each GC vial and vortexed for 2 min before
GC analysis. Fifty microliters of each sample was also pooled
and analyzed as a QC sample at the beginning and at the end
of the sequence, and after every five samples to check system
stability and performance of the analysis.
2.8 1H NMR spectroscopic analysis
1HNMRspectra were acquired using a BrukerDRX600MHz
spectrometer (Bruker Biospin, Karlsruhe, Germany), operat-
ing at 300 K, using the standard 1-dimensional NMRpulse se-
quence [relaxation delay-90°-t1-90°-tm-90°-acquire-FID]. The
water peak was suppressed by selective irradiation during the
relaxation delay of 2 s and mixing time (tm) of 100 ms; t1 was
fixed to 2 s. The 90° pulse length was adjusted to approxi-
mately 10s. A total of eight dummy scans and 64 scans were
recorded into 32 k data points with a spectral width of 20 ppm.
An exponential function corresponding to a line broadening
of 0.3 Hz was applied to each free induction decay (FID) prior
to Fourier transformation [15].
2.9 1H NMR spectroscopy data treatment
The resulting 1HNMR spectra were digitalized and imported
into Matlab 8.3 (MathWorks Inc. USA). The spectra were
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automatically corrected for phase and baseline distortions.
Peaks were referenced to the TSP signal at  0.0 for aque-
ous samples, whereas the lipid extracts were referenced to
the TMS signal at  0.0. The region containing the water res-
onance was removed in the aqueous fraction. Spectra were
normalized to the total area and modeled using a Matlab
script developed in-house [16]. Significant metabolites were
obtained after investigating correlations over correlation co-
efficients values higher than 0.7.
2.10 CE-MS analysis
CE-MS TOF experiments were performed using an Agilent
7100 CE system coupled to an Agilent 6224 Accurate-Mass
TOF spectrometer system (Agilent Technologies, Wilming-
ton, USA). The coupling was equipped with an electrospray
source. The CE unit was operated by 3D-CE ChemStation
Rev B.04.03 (Agilent Technologies, Wilmington, USA), and
MS data were acquired using a MassHunter WorkStation Ac-
quisition B.02.01 (Agilent Technologies, Wilmington, USA)
in centroid mode with a data acquisition rate of five spectra
per second. Separations were carried out in a fused-silica
capillary (Agilent) with an internal diameter of 50 m and a
total length of 60 cm in normal polarity with a background
electrolyte containing 0.1 mol/L formic acid solution. Before
each analysis the capillary was conditioned with a first flush
of 300 s of 2 M ammonium hydroxide, a second flush of 240 s
of deionizedwater and a third flush of 300 s of run buffer. The
capillary temperature was maintained at 25˚C. Samples were
injected hydrodynamically at 50mBar for 3 s andwere carried
out in a stacking manner. A voltage of 25 kV was applied
for 20 min. The sheath liquid was delivered at a flow rate of
0.6 mL/min with split 1:100, comprising of methanol/water
(70% v/v) and contained 1.0 mmol/l formic acid. The source
that delivers auxiliary liquid was set at 6 L/min.
The capillary voltage was set at 4 kV and the nitrogen gas
flow rate, which was 200°C, was 10 L/min. The nebulizer was
set to 10 psi 30 s after injection. The fragmentor and octupole
voltage were set to 150 and 750 V, respectively. A solution
containing 10mLwater, 90mLmethanol, 100L formic acid,
with two reference masses; 1, 600 L of 5 mmol/L purine,
and 600 L of 2.5 mmol/L HP 0921 that was infused directly
into the ion source. The referencemass spectra were collected
simultaneously with the analytical data and used for accurate
mass correction and highly accurate mass measurement in
theMS system. Amass acquisition range of 50–1700m/zwas
used.
The samples were analyzed in a randomized run with a
QC sample analyzed at the beginning of the run, every six
samples, and at the end of the sequence.
2.11 CE-MS data treatment
Data obtained by CE-MS were cleaned of background noise
and unrelated ions by the molecular feature extraction (MFE)
tool in MassHunter (B.04.00, Agilent). The molecular fea-
ture extraction is capable of creating a list of all possible
components represented by the full TOF mass spectral data
and migration times. This was obtained using the following
parameters: target data type of small molecules (chromato-
graphic); peaks with height  200 counts; Peak spacing tol-
erance = 0.0025; m/z, ± 7.0 ppm; isotope model = common
organic molecular; limited assigned change = 2. Alignment
was performed first on all samples with QC samples, and
later only for the samples under investigation. Corrections
applied for the alignment were 2% migration time correc-
tion, and ±10 ppm mass correction. Data were normalized
using total area normalization. The filtering and alignment
of the data were performed with GeneSpring version 12.6
(Agilent) selecting features in the range of 0.5–20 min. Filter-
ing was performed by eliminating features present in the QC
samples with a coefficient of variation above 30%. SIMCA
P+ 13.0 software (Umetrics, Umea˚, Sweden) was then used
for multivariate analysis. Variables with a |t-statistic|  1.96
(z-score, corresponding to the 97.5 percentile) [17] were con-
sidered significant.
2.12 UPLC-MS lipid profiling
BM samples were run on Acquity UPLC system (Waters Ltd.,
Elstree, UK) coupled to a Xevo-G2 quantitative QTOF mass
spectrometer (Waters MS Technologies, Ltd., Manchester,
UK). Chromatographic conditions have been previously es-
tablished [18]. Separation was performed using a CSH C18
(1.7 m, 2.1 × 100 mm) column (Waters Corporation, Mil-
ford, USA) at 55ºC. The mobile phase consisted of 0.1%
formic acid v/v and 10 mmol/L ammonium formate in 60:40
v/v ACN/H2O (A) and 0.1% formic acid v/v and 10 mmol/L
ammonium formate in 90:10 v/v IPA/ACN (B). Flow rate was
0.4 mL/min. The injection volume was 5 L.
MS was performed on a Xevo-G2 QTOF mass spec-
trometer (Waters Ltd., Manchester, UK) in both positive and
negative ion electrospray (ESI+ and ESI–) mode. The MS
parameters were: capillary voltage, 1.5 kV; sample cone volt-
age, 30 V; source temperature 120ºC; desolvation tempera-
ture and gas flow, 600ºC and 1000 L/h, respectively; cone gas
flow, 50 L/h and scan range 50–2000 m/z. For mass accu-
racy, a LockSpray interface was used with a 2 ng/L leucine
enkephalin (555.2645 amu) solution at 10 L/min as the lock
mass. Data were collected in centroid mode with lock mass
scans collected every 30 s and averaged over three scans to
perform mass correction.
A QC sample, prepared by combining equal aliquots of
all the samples, was used to ensure system suitability and
stability. The QC sample was injected at regular intervals
throughout the analytical run. This QC samples was also
used to condition the column (ten injections) and to obtain
structural information, using an automated MS/MS method
(data-dependent acquisition).
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2.13 UPLC-MS data treatment
Data acquisition and analysis was performed usingMassLynx
software version 4.1. Raw data files were converted toNetCDF
format. Data were then processed (noise filtered, aligned,
and normalized) using the freely available software package
XCMS in R. Features detected in individual samples were
grouped across the sample set and the minimum fraction
filter applied to exclude groups that contained features not
found in 50% of the samples, in each of the sample groups
(QC sample and study samples). Further filtering was per-
formedby eliminating features present in theQCsamplewith
a coefficient of variation above 30%. Data were normalized
using the median fold change [19]. SIMCA P+ 13.0 (Umet-
rics, Umea˚, Sweden) was then used for multivariate analysis.
Variables with a |t-statistic| 1.96 (z-score, corresponding to
the 97.5 percentile) [17] were considered significant.
2.14 HPLC-MS single phase analysis
A HPLC system (1200 series, Agilent Technologies, Wald-
bronn, Germany) coupled to an Agilent QTOF (6520) with
EI source was used to perform the global profiling analyses
on a single phase, as previously published [20], further infor-
mation on the analysis acquisition parameters for HPLC-MS
can be found in the SI.
The total run timewas 60min. QC samples were injected
at the beginning and at the end of the analysis and after every
five study samples.
2.15 HPLC-MS single phase data treatment
MassHunter Qualitative Analysis Software (Agilent R©, ver-
sion B.05.00) was used to clean background noise from the
spectral data and the MFE algorithm was used to export
molecular entities. The output generated anMFEfile contain-
ing a list of all molecular entities in the full TOFmass spectral
data for each sample. Primary data treatment (alignment and
filtering) was performed in mass profiler professional B.12.1
Agilent R© software. Signals in theHPLC chromatogramcorre-
sponding tomasses with a RSD less than 20% based on 10 in-
dependent replicates of a BMpoolwere retained formetabolic
characterization. In addition, features with abundance less
than 105 (positive mode) and 104 (negative mode), were dis-
carded. SIMCA P+ 13.0 (Umetrics, Umea˚, Sweden) was then
used for multivariate analysis. Variables with a |t-statistic| 
1.96 (z-score, corresponding to the 97.5 percentile) [17] were
considered significant.
2.16 GC-MS analysis
AGC instrument (Agilent 7890A) coupled to mass spectrom-
eter (Agilent 5975C) was used to perform the global profiling
analyses on a single phase [20], further information on the
analysis acquisition parameters for GC-MS can be found in
the SI.
QC samples were injected at the beginning and at the
end of the analysis and after every five study samples.
2.17 GC-MS data treatment
The Agilent MSD ChemStation Software was used to acquire
data. In order to perform retention index (RI) correction a
match score was assigned between the experimental FAME
mixture R© analyzed and theoretical RI values based on RI val-
ues contained in the Fiehn RTL library [21]. Retention index
comparison of spectra with the Fiehn RTL library was per-
formed in automated mass spectrometry deconvolution and
identification system (AMDIS) software v.2.69 for peak detec-
tion and deconvolution. The targets obtained and confirmed
from retention index search were used to build a bespoke
library after correcting retention times. NIST library was also
used for complementary identification.
An IS peak was used to examine the quality of the
chromatograms acquired by total ion chromatogram.
Metabolites present in the GC-MS profiles were identified
before multivariate analysis. Only compounds present in
 70% of all samples (QC samples and study samples)
were maintained for further statistical analysis. SIMCA P+
13.0 software (Umetrics, Umea˚, Sweden) was then used
for multivariate analysis. Variables with a |t-statistic|  1.96
(z-score, corresponding to the 97.5 percentile) [17] were
considered significant.
2.18 Metabolite identification
Metabolites were identified from 1HNMR spectra by employ-
ing the online database HMDB, using chemical shift infor-
mation from the 1 and 2 dimensional experiments collected.
Peaks that proved difficult to assign were assigned by statis-
tical total correlation spectroscopy, using an in-house Matlab
script [16]. Confirmation of metabolite identity was obtained
using spiked in standards, where necessary.
Metabolites detected using CE-MS were tentatively iden-
tified by comparing high mass accuracy data (with less than
5 ppm tolerance) against standards analyzed for comparison,
as well as against information contained in HMDB. Isotopic
distribution was also used for particular chemical formula
confirmation, and standards were injected, when available,
in case different formulas corresponded to the same mass.
UPLC-MSmetabolite annotationwas achieved by search-
ing m/z values against online databases including METLIN,
Lipidmaps, and HMDB with the mass error set to 10 ppm.
In order to identify the lipid species, MS/MS data were in-
spected to obtain fragmentation patterns and the presence
of head groups, increasing confidence in the identity of the
metabolite assigned.
Tentative identification of metabolites detected by
HPLC-MS was undertaken by comparing accurate masses
against the online university database, CEU-mass mediator
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(http://ceumass.eps.uspceu.es/mediator/), which uses
KEGG, METLIN, and Lipidmaps databases, with the mass
error set to 10 ppm. Results were curated using MassHunter
to compare potential hits against the experimental isotopic
pattern distribution and retention time prediction.
For GC-MS data, compounds were identified by com-
paring the experimental mass fragmentation patterns with
those available in the NIST 08 and Fiehn RTL mass spec-
tral libraries. Also the AMDIS software v.2.69 was used for
automatic peak identification and deconvolution [22].
2.19 Analytical performance
In order to assess the reliability of the methods for compar-
ing differences among metabolites the RSD was calculated
for each of the analytical techniques using a set of signals
from between 5 and 10 metabolites, selected so as to rep-
resentatively and evenly cover the full metabolite profile as
far as possible. The metabolites chosen, together with their
% RSD values are provided in the Supporting Information
Table 1.
2.20 Multivariate analysis
Differences among samples were evaluated using SIMCA
P+ 13.0 multivariate modelling software (Umetrics, Swe-
den), which was used to plot data and perform multivari-
ate analysis using pattern recognition techniques including
principal components analysis (PCA), partial least squares
projections to latent structures-discriminant analysis (PLS-
DA), and orthogonal partial least squares projections to latent
structures-discriminant analysis (OPLS-DA). These model-
ing techniques were carried out on the data obtained from
the different analytical platforms to establish systematic dif-
ferences in BM composition over the first three months of
lactation.
For the purpose of analysis, samples were split into
three time groups; samples collected on days 1–5 postbirth,
days 6–10 postbirth, and more than 10 days postbirth, until
day 80.
2.21 Reagents
All standards, chemicals, reagents, and solvents used are
listed in the Supporting Information.
3 Results
3.1 Profile characterization
Each analytical platform generated a set of metabolites
present in human breast milk, some of which were unique to
that platformand someofwhichwere detected by two ormore
platforms. The total coverage of the BMmetabolome from the
combined techniques consisted of 710 identified metabolites
using a pooled BM sample. The structural identities of some
metaboliteswere validated experimentallywith the remainder
identified based on matching of retention times and m/z ra-
tios from databases, 15% of the identifications were validated
experimentally. Seventy BM samples, collected between birth
and three months postnatal age, were analyzed using multi-
platform analytical techniques; HPLC-MS, UPLC-MS, GC-
MS, CE-MS, and1H NMR. Metabolites present in the profiles
of each of these techniques were, as far as possible, assigned
(Supporting Information Fig. 1, and Supporting Information
Tables 2–4).
3.2 1H NMR spectroscopy profile characterization
Analyzing the aqueous fraction of BM using 1H NMR spec-
troscopy allowed the identification of 52 metabolites. In the
spectra of the organic extracts 14 peaks were identified,
however, these peaks do not always correspond to specific
molecules, but represent lipid classes or distinct proton envi-
rons within the lipid. Similarly, in the aqueous phase there is
much overlap between peaks, especially from sugar groups,
meaning identification of the HMO are not definitive but
relate to the proton environment. The aqueous and lipid
fractions are displayed in Fig. 2A and B, respectively with
metabolites identified outlined in Tables 1 and 2. The main
metabolite classes identified from the aqueous fraction in-
cluded; monosaccharides, disaccharides, HMO, amino acids,
and their derivatives, choline containing molecules, interme-
diates of the tricarboxylic acid cycle, ketones, and short chain
fatty acids.
3.3 CE-MS profile characterization
Analyzing the aqueous fraction of BM using CE-MS
yielded 23 identified metabolites from the electropherogram;
Fig. 2C displays an extracted ion chromatogram of a repre-
sentative sample. Metabolites identified were mainly amino
acids and their derivatives, organic acids and nicotinamide,
glycylglycine and cytosine/dine, Table 3.
3.4 UPLC-MS lipid fraction profile characterization
The lipid fraction of BM, obtained from the dual phase
extraction, analyzed using UPLC-MS in both negative
and positive ionization mode was analyzed. The resulting
chromatograms were characterized, allowing the tentative
identification of 105 metabolites (Supporting Information
Table 4). The base peak chromatogram for a representative
sample in negative and positive ionization mode is pre-
sented in Fig. 2D and E, respectively, showing regions of
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Figure 2. Profiles of BM analyzed via: (A) Median 1H NMR spectrum of aqueous fraction of BM, 1 = Fucose, 2 = Lactate, 3 = Alanine, 4 =
Butyrate, 5 = N-acetyl glutamine, 6 = Acetate, 7 = N-acetyl neuraminic acid, 8 = Glutamine, 9 = Glutamate, 10 = Citrate, 11 = Creatine, 12
= Creatinine, 13 = Choline, 14 = Phosphocholine, 15 = Glycerophosphocholine, 16 = Lactose, 17 = Taurine, 18 = Glucose, 19 = Galactose.
(B) Median 1H NMR spectrum of lipid fraction of BM 1 = Cholesterol, 2 = Terminal CH3, 3 = Omega 3 terminal CH3, 4 = Saturated CH2,
5 = CH2-CH2-COOH, 6 = Unsaturated fatty acids CH2-CH = CH, 7 = CH2-COOH, 8 = Docosahexaenoic acid, = CH-CH2-CH2-COOH, 9 =
Polyunsaturated fatty acid, = CH-CH2-CH = , 10 = Phosphatidylcholine, -N(CH3)3, 11 = Phospholipid, 12 = Glyceryl C1,3, 13 = Glyceryl C2,
14 = Unsaturated fatty acids, -CH = CH-. (C) Aqueous fraction of BM analysed using CE-MS in positive ionization mode; 1 = Creatinine,
2 = Lysine, 3 = Nicotinamide, 4 = Arginine, 5 = Carnitine, 6 = Acetyl-L Carnitine, 7 = Cytosine, 8 = Cytidine, 9 = Creatine, 10 = Alanine,
11 = 5-amino Valeric acid/valine, 12 = N-methyl-L-Valine/leucine/isoleucine, 13 = Serine, 14 = Tryptophan, 15 = Threonine, 16 = Glycyl-
glycine, 17 = Methionine, 18 = Citrulline, 19 = Phenylalanine, 20 = Glutamic acid, 21 = Tyrosine, 22 = Cystine, 23 = Aspartic acid. (D)
UPLC-MS; lipid fraction of BM analysed in negative ionization mode, tentative identifications are shown in Supporting Information Table
4. (E) UPLC-MS; lipid fraction analyzed using positive mode, tentative identifications are shown in Supporting Information Table 4. (F)
GC-MS single phase assignments from 6–19 min 1 = Pyruvic acid, 2 = Lactic acid (Standard confirmed), 3 = Glycolic acid, 4 = Valine 1, 5
= Alanine 1, 6 = 2-Hydroxybutyric acid, 7 = 2-Furoic acid, 8 = Isoleucine 1, 9 = Valine 2, 10 = Urea (Standard confirmed), 11 = Benzoic
acid, 12 = Caprylic acid, 13 = Glycerol (Standard confirmed), 14 = Phosphoric acid, 15 = Proline 2 (Standard confirmed), 16 = Glycine, 17
= Succinic acid, 18 = Glyceric acid, 19 = Serine 2 (Standard confirmed), 20 = Threonine 2, 21 = Capric acid, 22 = Malic acid, 23 = Adipic
acid, 24 = Threitol, 25 = Pyroglutamic acid, 26 = Glutamic acid 1, 27 = Creatinine, 28 = Glutamic acid 2 (Standard confirmed), 29 = Lauric
acid, 30 = Lyxose 1/Lyxosylamine 1, 31 = Lyxose 2/Lyxosylamine 2/Ribose, 32 = Xylitol, 33 = Fucose 1, 34 = Fucose 2, 35 = Citric acid
(Standard confirmed), 36 = Hippuric acid 2, 37 = Myristic acid, 38 = Tagatose 1/Sorbose 2/Sorbose 1/Fructose 1, 39 = Tagatose 2/Fructose
2/Fructose 1, 40 = Galactose 1/ Mannose 1/Allose 1/Gluconic acid lactone 1, 41 = Glucose 1/Talose 1 (Standard confirmed), 42 = Altrose
2/Mannose 2/Glucose 2/Allose 2/Talose 2, 43 = Mannitol/Sorbitol, 44 = 1-Hexadecanol, 45 = Palmitoleic acid, 46 = Palmitic acid.
a representative chromatogram with metabolites with the
highest intensity identified. In negative ionization mode,
the main metabolites identified were saturated fatty acids,
monounsaturated fatty acids and polyunsaturated fatty acids
while in positive ionization mode the main classes of lipid
identified were triacylglycerols and phospholipids.
3.5 HPLC-MS single phase profile characterization
Characterization of the chromatogram resulting from
HPLC-MS analysis of a pooled sample from the single
phase extraction was done as thoroughly as possible (Sup-
porting Information Fig. 1) (adapted from a previously
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Table 1. Peak Assignments for 1H NMR Spectrum from the aqueous and lipid fraction of human BM
# Compound name 1D /2D Group Assignment 1H () 13C () Multiplicity Metabolite class
1 2-Oxoglutarate 2D 2.42, 2.99 33.4, 38.6 (t) Citrate cycle
2 2’-Fucosyllactose 2D Fuc(1-2)
Gal(1-4)
CH-1
CH-5
CH3-6
CH-1
5.32
4.23
1.24
4.53
102.3
69.9
18.1
103
HMO
3 3’-Fucosyllactose 2D Fuc(1-3)Glc
Fuc(1-3)Glc
CH-1
CH3-6
CH-1
5.39
1.19
5.44
101.3
18.2
101.1
HMO
4 3’-Sialyllactose 2D Neu5Ac(2-3) CH-5
CH-3
CH-3
3.85
2.75
1.78
54.5
42.7
42.6
HMO
5 6’-Sialyllactose 2D Neu5Ac(2-6) CH-3
CH-3’
2.73
1.73
42.9
42.9
HMO
6 Lacto-N-neoDiFucohexaose 2D Fuc(1-3)GlcNAc CH-1
CH-5
5.19
4.3
102.3
69.5
HMO
7 Lacto-N-neofucopentaose/
Lacto-N-neotetraose/
Para-Lacto-N-neohexaose/
Lacto-N-neooctaose/
Lacto-N-neofucopentaose/
Galacto-N-neoPentaose
2D Gal(1-4)GlcNAc CH-1
CH-4
4.43
4.15
104.6
71.34
HMO
8 Lactodifucotetraose 2D Fuc(1-2)
Fuc(1-3)Glc
Fuc(1-3)Glc
CH-1
CH-1
CH3-6
CH-1
5.29
5.4
1.19
5.46
102.3
101.5
18.34
101.21
HMO
9 Lacto-N-difucohesaose I Fuc(1-2)
GlcNAc(1-6)
CH-1
CH-5
CH-1
5.16
4.35
4.62
102.3
69.1
106.17
HMO
10 Lacto-N-difucohesaose II Fuc(1-4)
Fuc(1-3)Glc
Fuc(1-3)Glc
Gal(1-4)
CH-1
CH3-6
CH-1
CH-1
CH3-6
CH-1
5.03
1.18
5.38
5.43
1.14
4.52
100.6
18.34
101.71
101.5
18.34
105.7
HMO
11 Lacto-N-fucopentaose II Fuc(1-4) CH-1
CH3-6
5.03
1.18
100.81
18.34
HMO
12 Lacto-N-fucopentaose III Fuc(1-3)GlcNAc
Fuc(1-3)GlcNAc
CH3-6
CH-1
CH3-6
1.19
5.13
1.19
18.34
101.51
18.34
HMO
13 LNFP V Fuc(1-3)Glc CH-1
CH3-6
5.39
1.19
101.51
18.34
HMO
Fuc(1-3)Glc CH-1
CH3-6
5.44
1.19
101.22
18.34
14 Lacto-N-neotetraose CH-1 4.35 104.6 HMO
15 Lacto-N-tetraose CH-1
CH-2
4.35
3.51
104.6
71.5
HMO
16 Acetate 1D 1.92 (s) Organic acid
17 Acetone 1D 2.22 (s) Ketone
18 Alanine 1D, 2D 1.48 19.0 (d) Amino Acid
19 Aspartate 1D, 2D 2.71, 2.8 39.3, 39.4 (dd), (dd) Amino Acid
20 Butyrate 1D 0.89, 1.55 (t), (m) Short chain fatty
acids
21 Caprate 1D, 2D 1.27 (m) Short chain fatty
acids
22 Caprylate 1D 1.27 (m) Short chain fatty
acids
23 Carnitine 1D, no
2D
3.25 (s) Amino acid
derivative
(Continued)
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Table 1. Continued
# Compound name 1D /2D Group Assignment 1H () 13C () Multiplicity Metabolite class
24 Choline 1D, 2D 3.18 58.4 (s) Cholines
25 Citrate 1D, 2D 2.53, 2.66 48.7, 48.7 (dd) Citrate cycle
26 Creatine 1D 3.04 (s) Organic Acid
27 Creatine phosphate 1D (s) Organic Acid
28 Creatinine 1D 3.048 (s) Organic Acid
29 Ethanolamine 1D, 2D 3.14 44.18 (t) Other
30 Formate 1D 8.46 (s) Organic acid
31 Fucose 1D, 2D 1.18, 1.23, 3.42,
4.15, 4.53, 5.2
(d), (d), (m), (m),
(d), (d)
Monosaccharide
32 Galactose 2D 5.28 95 (d) Monosaccharide
33 Glucose 1D, 2D CH-1 4.65 98.82 (d) Monosaccharide
34 Glutamate 1D 2.13, 2.35 (m), (m) Amino Acid
35 Glutamine 1D 2.13, 2.44 (m), (m) Amino Acid
36 Lactate 1D, 2D 1.33 22.9 (d) Organic acid
37 Lactose 1D, 2D 3.3, 3.54-3.97, 4.46,
4.68, 5.24
(t), (multiple
peaks), (d), (d), (d)
Disaccharide
38 Isoleucine 1D 0.92 (t) Amino Acid
39 Leucine 1D 0.96, 1.7 (t), (m) Amino Acid
40 Lysine 2D 3.01 42.1 (t) Amino Acid
41 Methanol 1D, 2D 3.37 51.4 (s) Other
42 Methionine 2D 2.1 17.0 (m) Amino Acid
43 N-Acetylneuraminic acid 1D 2.06 (s) Monosaccharide
44 N-Acetylglucosamine 1D 2.04, 5.2 (s), (d) Monosaccharide
45 O-Acetylcarnitine 1D (s) Amino acid derivative
46 O-Phosphocholine 1D 3.2 (s) Cholines
47 sn-Glycero-3-
phosphocholine
1D, 2D 3.22 56.7 (s) Cholines
48 Succinate 1D, 2D 2.4 3.68 (s) Citrate cycle
49 Taurine 2D 3.41 38.3 (t) Amino acid derivative
50 Tyrosine 2D 6.83, 7.13 118.3,
133.2
(m), (m) Amino Acid
51 Urea 1D 5.78 Other
52 Valine 1D 0.99, 1.02 (dd) Amino Acid
published paper, copyright granted [20]). This resulted in
the tentative identification of 289 individual compounds in
positive mode ionization, and 126 metabolites in negative
ionization mode, of which 23 were in common, giving a
total of 392 individual metabolites, Supporting Information
Tables 2 and 3. As described in previous publications fatty
acids, glycerophospholipids, sphingolipids, sterol lipids,
monoacylglycerols (MG), diacylglycerols (DG), triacylglyc-
erols (TG), and cholesteryl esters were observed [12, 23]
[24–26].
3.6 GC-MS single phase profile characterization
A pooled sample of BM was analyzed in a single phase by
GC-MS and metabolites identified. The total compound
chromatogram of the extraction, displayed in Fig. 2F,
highlights a range of molecules including; amino acids,
fatty acids, organic acids, hexose, and pentose sugars, TCA
intermediates, cholesterol, and disaccharides. A total of 56
metabolites were identified, displayed in Table 4 (reproduced
with permission from Villasen˜or et al.) [12].
Table 2. Peak assignments for 1H NMR spectrum from the lipid
fraction of BM
Peak Proton Chemical Multiplicity
number shift(s) ()
1 Terminal -CH3 0.88 (t)
2 Terminal -CH3 in 3 fatty acids 0.97 (t)
3 -CH2- 1.25 (s)
4 -CH2-CH2-COOH 1.61 (s)
5 -CH2-CH=CH- 2.01 (q)
6 -CH2-COOH 2.30 (t)
7 =CH-CH2-CH2-COOH 2.34 (t)
8 =CH-CH2-CH= 2.77 (t)
9 -N(CH3)3 Phosphatydylcholine 3.33 (s)
10 Glyceryl, C1, 3, 2 4.14, 4.29, 5.26 (m), (m), (m)
11 -CH=CH- 5.34 (m)
3.7 Core and unique in BM metabolome signatures:
Comparison of platform capabilities
in metabolite coverage
With regard to analytical platforms that identified aqueous
metabolites, some overlap between platforms was noted, but
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Table 3. Identification of metabolites from the aqueous fraction of BM using CE-MS
Metabolite Metabolite class Formula [M+H]+ (Da) Experimental
mass (Da)
Mass error
(ppm)
Migration
time (min)
1 Creatinine Organic Acid C4H7N3O 114.0662 114.0663 0.9 2.8
2 Lysine Amino acid C6H14N2O2 147.1128 147.1127 –0.7 3
3 Nicotinamide Vitamin C6H6N2O 123.0553 123.0552 –0.8 3.1
4 Arginine Amino acid C6H14N4O2 175.119 175.119 0.0 3.1
5 Carnitine Amino acid derivative C7H15NO3 162.1125 162.1125 0.0 3.4
6 Acetyl-L-carnitine Amino acid derivative C9H17NO4 204.123 204.1232 1.0 3.7
7 Cytosine Nucleotide C4H5N3O 112.0505 112.0504 –0.9 3.7
8 Cytidine Nucleoside C9H13N3O5 244.0928 244.0929 0.4 3.7
9 Creatine Organic Acid C4H9N3O2 132.0768 132.0769 0.8 4.2
10 Alanine Amino acid C3H7NO2 90.055 90.0551 8.7 4.5
11 5-Aminovaleric acid/Valine Amino acid C5H11NO2 118.0863 118.0864 0.8 4.9
12 n-Methyl-L-Valine/Leucine/Isoleucine Amino acid C6H13NO2 132.1019 132.102 0.8 5
13 Serine Amino acid C3H7NO3 106.0499 106.0499 0.0 5.2
14 Tryptophan Amino acid C11H12N2O2 205.0972 205.0971 –0.5 5.2
15 Threonine Amino acid C4H9NO3 120.0655 120.0654 –0.8 5.3
16 Glycylglycine Dipeptide C4H8N2O3 133.0608 133.0609 0.8 5.2
17 Methionine Amino acid C5H11NO2S 150.0583 150.0582 –0.7 5.3
18 Citrulline Amino acid C6H13N3O3 176.103 176.1027 –1.7 5.4
19 Phenylalanine Amino acid C9H11NO2 166.0863 166.0861 –1.2 5.4
20 Glutamic acid Amino acid C5H9NO4 148.0604 148.0603 –0.7 5.5
21 Tyrosine Amino acid C9H11NO3 182.0812 182.0811 –0.5 5.6
22 Cystine Amino acid C6H12N2O4S2 241.0312 241.0311 –0.4 5.8
23 Aspartic acid Amino acid C4H7NO4 134.0448 134.0445 –2.2 6.1
each platformcontributed an additional unique set ofmetabo-
lites. For example, GC-MS and 1H NMR generated signals
for 21 common metabolites, including sugars, amino acids,
fatty acids, and tricarboxylic acids, of which five were also in
common with the CE-MS generated profile (alanine, creati-
nine, glutamate, isoleucine, and valine). Both 1H NMR and
GC-MS characterized several sugars including galactose, glu-
cose, and lactose, while GC-MS additionally profiled several
polyols (mannitol, sorbitol,myo-inositol, threitol, xylitol). GC-
MS uniquely detected numerous medium to long chain fatty
acids, whereas HMO and short chain fatty acids were profiled
by 1H NMR spectroscopy. CE-MS gave the most comprehen-
sive amino acid profile, and both 1HNMR andCE-MS charac-
terized several carnitines. TheUPLC-MSprofiles, in both pos-
itive and negative ionizationmode of the lipid fraction yielded
data from sphingomyelins, phosphocholines, phospho-
ethanolamines, and di- and triglycerides. It was observed that
some high abundance metabolites from the Folch extraction
were detected in both the polar and nonpolar fractions, indi-
cating that thismethodwould not be the ideal choice for quan-
titation since distribution of metabolites across two compart-
ments makes calculation of total concentration less accurate.
3.8 Analytical performance; RSD
Prior to analysis, system stability and performance were as-
sessed using QC samples. Additionally, QC samples were
analyzed every few samples throughout the run to ensure
good instrumental performance over the run. This allows for
the repetition of sample analysis if necessary. Data quality
was also evaluated prior to the multivariate analysis, by build-
ing a PCA model including samples and QC samples, which
cluster into the center of the plot. Moreover, data arising from
the QCs were used to filter instrumental noise from the MS
data of the breast milk samples.
The RSD was calculated for each of the methods, and
was used to establish the reproducibility of the methods used
(Supporting Information Table 1). All of the methods were
found to be robust and reproducible. Of all the methods, 1H
NMR of the aqueous BM fraction was found to be the most
reproducible, with mean RSD value of 6.4% and range of
0.1–24%, while GC-MS gave a similar mean value of 7.65%
(1.8–18.6%). All the LC-MSmethods also showed good repro-
ducibility across the selected metabolites, with mean values
of 8.15% (4.6–15%), for the single phase HPLC extraction
method and mean RSDs of 7.95 and 13.56% for the positive
and negative mode of the Folch extracted samples, respec-
tively (ranges, 3.2–18.3% and 2.7–26.6%). The mean RSD for
the CE-MS metabolites was the weakest in terms of repro-
ducibility, 24.18%, but was still within the accepted cut off
value of 30% RSD (12.7–29.1%).
3.9 Multiplatform assessment of metabolite
alterations in BM over time
The multiplatform approach was applied to a set of BM sam-
ples in order to identifywhichmetaboliteswere altered in con-
centration over lactation between the three different groups;
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Table 4. Compounds identified in BM by GC-MS, (data adapted from Villasen˜or et al. [12])
No. Metabolite class Metabolite Target ion (Da) Retention time
1 Organic acid Pyruvic acid 174 6.76
2 Organic acid Lactic acid (standard confirmed) 147 6.92
3 Organic acid Glycolic acid 147 7.13
4 Amino acid Valine 1 72 7.43
5 Amino acid Alanine 1 116 7.53
6 Organic acid 2-Hydroxybutyric acid 147 7.87
7 Aromatic homomonocyclic compounds 2-Furoic acid 125 7.99
8 Amino acid Isoleucine 1 86 8.57
9 Amino acid Valine 2 144 9.14
10 Aliphatic acyclic compounds Urea (standard confirmed) 147 9.54
11 Aromatic homomonocyclic compounds Benzoic acid 179 9.62
12 Fatty acids Caprylic acid 201 9.81
13 Sugar alcohols Glycerol (standard confirmed) 147 9.92
14 Nonmetal oxoanionic Compounds Phosphoric acid 299 10
15 Amino acid Proline 2 (standard confirmed) 142 10.28
16 Amino acid Glycine 174 10.39
17 Carboxylic acids Succinic acid 147 10.48
18 Sugar acids Glyceric acid 189 10.74
19 Amino acid Serine 2 (standard confirmed) 204 11.14
20 Amino acid Threonine 2 218 11.48
21 Fatty acids Capric acid 229 12.39
22 Organic acids Malic acid 233 12.8
23 Organic acids Adipic acid 111 13
24 Sugar alcohols Threitol 217 13.06
25 Pyrrolidines Pyroglutamic acid 156 13.21
26 Amino acid Glutamic acid 1 174 13.33
27 Lactams Creatinine 115 13.62
28 Amino acid Glutamic acid 2 (Standard confirmed) 246 14.37
29 Fatty acids Lauric acid 257 14.75
30 Sugar acids Lyxose 1/Lyxosylamine 1 103 14.89
31 Sugar acids/monosaccharides Lyxose 2/Lyxosylamine 2/Ribose 103 15.06
32 Sugar alcohols Xylitol 217 15.47
33 Monosaccharides Fucose 1 117 15.59
34 Monosaccharides Fucose 2 117 15.73
35 Carboxylic acids Citric acid (standard confirmed) 273 16.57
36 Amino acids and derivatives Hippuric acid 2 105 16.88
37 Fatty acids Myristic acid 117 16.91
38 Monosaccharides Tagatose 1/Sorbose 2/Sorbose 1/Fructose 1 103 17.12
39 Monosaccharides Tagatose 2/Fructose 2/Fructose 1 103 17.24
40 Monosaccharides Galactose 1/Mannose 1/Allose 1/Gluconic acid lactone 1 205 17.28
41 Monosaccharides Glucose 1/Talose 1 (standard confirmed) 319 17.4
42 Monosaccharides Altrose 2/Mannose 2/Glucose 2/Allose 2/Talose 2 319 17.54
43 Fatty alcohols Mannitol/sorbitol 319 17.87
44 Fatty alcohols 1-Hexadecanol 299 17.95
45 Fatty acids Palmitoleic acid 311 18.68
46 Fatty acids Palmitic acid 117 18.88
47 Monosaccharides N-acetyl-D-mannosamine 1/N-acetyl-D-mannosamine 2 319 19.19
48 Cyclic alcohols Myo-inositol (standard confirmed) 318 19.32
49 Fatty acid esters Methyl stearate (internal standard) 74 19.66
50 Fatty acids Heptadecanoic acid 327 19.81
51 Fatty acids Linoleic acid 75 20.42
52 Fatty acids Oleic acid 339 20.48
53 Fatty acids Stearic acid (standard confirmed) 341 20.69
54 Fatty acids Arachidic acid 369 22.37
55 Disaccharides Sucrose 361 24.1
56 Disaccharides Lactose 1 361 24.46
57 Disaccharides Trehalose/maltose 1/maltose 2 361 24.91
58 Disaccharides Galactinol 1 204 26.3
59 Steroids and steroid derivatives Cholesterol 129 27.64
Numbers after identification correspond to the number of trimethylsilyl groups found on the molecule after derivatization.
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Table 5. PCA scores plots, white diamonds represent samples taken 1–5 days post-birth, black squares 6–10 days, white stars >10 days,
model characteristics are displayed below
PCA models R2 Components Outliers t[1] t[2] Scaling
A NMR aqueous 0.406 2 3 0.27 0.128 UV
B CE-MS; Positive mode 0.333 1a) 0 0.23 Par
C HPLC-MS, 0.457 2 2 0.37 0.08 UV
D NMR Lipid 0.484 2 3 0.35 0.12 UV
E UPLC-MS; Positive mode lipid 0.567 2 0 0.39 0.17 Par
F UPLC-MS; Negative mode lipid 0.331 2 0 0.23 0.1 UV
G GCMS, Single phase 0.337 2 1 0.19 0.14 UV
a) Second component was used for plotting purposes only.
Table 6. OPLS-DA model values and descriptive information of models run to identify metabolites included in Table 7
OPLS-DA models Pairwise model R2X R2Y Q2 Components Scaling
A NMR aqueous 1 versus 2
2 versus 3
1 versus 3
0.381
0.41
0.412
0.582
0.813
0.927
0.249
0.713
0.866
2 UV
B CE-MS; Positive mode 1 versus 2
2 versus 3
1 versus 3
0.331
0.249
0.34
0.984
0.988
0.967
0.766
0.301
0.735
2 Par
C HPLC-MS, single phase 1 versus 2
2 versus 3
1 versus 3
0.407
0.405
0.486
0.879
0.848
0.844
0.467
0.54
0.761
2 UV
D NMR Lipida) 1 versus 2
2 versus 3
1 versus 3
0.462
0.443
0.416
0.567
0.455
0.572
−0.327
0.167
−0.05
2 UV
E Lipid UPLC-MS;
Positive mode
1 versus 2
2 versus 3
1 versus 3
0.246
0.622
0.564
0.959
0.792
0.837
0.489
0.429
0.531
2 Par
F Lipid UPLC-MS;
Negative modea)
1 versus 2
2 versus 3
1 versus 3
0.294
0.346
0.356
0.932
0.962
0.938
0.127
0.165
0.43
2 UV
G GC-MS, single phase 1 versus 2
2 versus 3
1 versus 3
0.401
0.192
0.315
0.959
0.975
0.916
0.7
0.544
0.237
2 UV
a) These models have a low predictive capability.
days 1–5 postbirth (group 1), 6–10 days postbirth (group 2)
and 10 days postbirth (group 3). First, PCA models, pro-
vided in Supporting Information Fig. 2, model details shown
in Table 5, show that differentiation of samples over time ac-
cording to inherent similarity in chemical composition was
apparent only for 1H NMR and CE-MS analysis of the aque-
ous fraction, and for the models constructed from the single
phase extraction method run using HPLC-MS, PCA R2X val-
ues; HPLC-MS single phase extractionR2X= 0.457, 1HNMR
of the aqueous fractionR2X= 0.406, andGC-MSR2X= 0.337
CE-MS R2X = 0.333, ranked in descending order of strength,
gave relatively strong models defining temporal changes in
BM composition. PLS-DA models comparing the three time
groups against one another were computed for each of the
analytical methods used; these models displayed a gradual
change in the composition of BM in relation to postnatal age
(data not shown) affecting the quality of the models.
For this reason, pairwise analysis using OPLS-DA was
selected as the most suitable method to establish which
metabolites changed over time, comparing groups 1 versus
2, 1 versus 3 and 2 versus 3. As shown in Table 6, each
technique yielded strong models indicating significant sys-
tematic differences in BM composition over time, with the
exception of models corresponding to the NMR lipid phase
and UPLC-MS lipid phase in negative ionization mode, with
these models showing a poor capability of prediction. Cross-
validated scores plots corresponding to the OPLS-DAmodels
can be found in the Supporting Information Figs. 3–5.
Metabolites identified from the OPLS-DA models as
altering between time groups are displayed in Table 7.
Changes identified in BM composition over the first few
days of lactation include an increase in the relative concen-
trations of di- and triacylglycerols along with a more sus-
tained increase in lactose, several amino acids, and short
and medium chain fatty acids. Conversely a time depen-
dent decrease was observed in multiple HMO, several phos-
phocholines, and energy metabolites such as citrate and
pyruvate.
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Table 7. Metabolites identified as changing in abundance in breast milk samples collected at different times postbirth
Class Metabolite 1st 5 days versus
day 6–10
1st 5 days versus
day +10
Day 6–10 versus
day +10
Amino acids Alanine A
Glutamine A A
Acids 3,4 Hydroxymandelic acid g
Butyrate A A
Citrate a a a
Taurine fa)
Pyruvic acid g
Ceramides Glucosyl Ceramide (36:2) Fa)
Ceramide (20:4) c
PE-Ceramide (38:2) fa)
PI-Ceramide (40:0) fa)
PE-Ceramide (38:2)
Diacylglycerols Diacylglycerol (24:0) C
Diacylglycerol (26:0) C
Diacylglycerol (28:2) C
Diacylglycerol (30:2) C
Diacylglycerol (34:0) E
Diacylglycerol (34:1) E
Diacylglycerol (34:3) E E
Diacylglycerol (40:7) C E
Diacylglycerol (44:10) e e
Prenol Lipids Tocopherol g g
Pyrimidine Nucleosides N4-Acetylcytidine B
Amino Acids Derivatives N-Acetyl glutamine a a a
Steroids and Steroid Derivatives Cholesteryl stearate fa)
Cholesterol da), g
Sugar alcohols Glycerol G
Phthalic Acid and Derivatives Dioctyl phthalate G
Fatty Acid Esters Methyl Stearate G
Fatty Acids 11S-hydroxy-hexadecanoic acid Fa)
9,12-octadecadienoic acid G G
Arachidonic Acid C
Caprylic acid Fa) Fa)
3-Hydroxycapric acid Fa)
Hexadecenoic acid Fa)
Myristic acid g
Oleic acid G
Palmitoleic acid G
Lauric acid G
Linoleic acid G G
Polyunsaturated FA da)
Terminal CH3 on omega 3 fatty acids da)
Saccharides Fucose (from HMO) a a, g a
D-Glucosaminic acid (from HMO) g g
N-Acetyl neuraminic acid (from HMO) a a a
Glucose G G
Lactose A, G A A
Gluconic acid lactone G
Glycerophosphocholines Glycerophosphocholine (18:0) e
Glycerophosphocholine (34:0) e e
Glycerophosphocholine (32:0) e e
Glycerophosphocholine (32:1) e
Glycerophosphocholine (30:0) e e e
Glycerophosphocholine (38:5) fa)
Glycerophosphocholine (34:2) e e
Glycerophosphocholine (36:1) e c
Glycerophosphocholine (36:2) E
(Continued)
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Table 7. Continued
Class Metabolite 1st 5 days versus
day 6–10
1st 5 days versus
day +10
Day 6–10 versus
day +10
Glycerophosphocholine (36:3) e
Glycerophosphocholine (36:4) fa)
Glycerophosphocholine (40:7) fa)
Glycerophosphocholine A A
Glycerophospho-ethanolamines Glycerophosphoethanolamine (40:6) Fa)
Glycerophosphoethanolamine (36:2) E
Glycerophosphoethanolamine (42:3) fa)
Glycerophosphoethanolamine (44:2) fa)
Glycerophosphoserines Glycerophosphoserine (30:3) Fa)
Glycerophosphoserine (18:1) fa)
Glycererophosphoglycerol Glycerophosphoglycerols (44:7) fa)
Glycerphosphoinositols Glycerophosphoinositol (35:2) fa)
Glycerophosphoinositol (32:0) E
Glycerophosphoinositol (37:4) fa)
Monoacylglycerols Monoacylglycerol (18:3) b b
Sphingomyelins Sphingomyelin (42:0) Fa)
Sphingomyelin (34:1) e e
Sphingomyelin (36:3) c
Sphingomyelin (38:1) e
Triacylglycerols Triacylglycerol (34:0) E e
Triacylglycerol (36:0) E e
Triacylglycerol (38:0) E e
Triacylglycerol (42:1) E e
Triacylglycerol (42:2) E e
Triacylglycerol (44:2) E e
Triacylglycerol (45:1) Fa)
Triacylglycerol (48:1) e fa)
Triacylglycerol (48:4) e
Triacylglycerol (48:5) e
Triacylglycerol (50:2) e
Triacylglycerol (51:2) C
Triacylglycerol (51:7) F
Triacylglycerol (52:2) e E
Triacylglycerol (55:9) fa)
Triacylglycerol (58:2) c
Triacylglycerol (60:3) c c c
a) These alterations were identified in models possessing a low predictive capability.
Capitals relate to higher concentration in the later time group, while lower case letters refer to metabolites that were decreased in
abundance in the later time point. NMR aqueous A, a; CE-MS aqueous B, b; HPLC-MS single phase C, c; NMR lipid D, d; UPLC-MS
positive E, e; UPLC-MS negative F, f; GC-MS single phase G, g.
4 Discussion
We have created the most comprehensive metabolic map of
BM to date using four different analytical platforms and two
sample preparation techniques, with absolute (15%) and ten-
tative identification of 710 metabolites; previous studies have
commonly identified between 50 and 100 metabolites. Addi-
tionally, we have demonstrated the utility of a multiplatform
analytical technique to investigate questions of clinical and bi-
ological importance by reporting the changes in abundance
of these metabolites over the first 3 months of lactation, com-
paring the utility of the different platforms.
In regard to previous studies employing metabonomic
strategies to investigate breast milk composition, both
Smilowitz et al. and Pratico et al. identified differences be-
tween samples based on the profiles of HMO secreted us-
ing 1H NMR spectroscopy [7, 9]. Previous research has also
employed MS to analyze human BM, these studies have pri-
marily focused on either the lipid content [11], or diversity
of HMO present in BM [5]. In addition, a study optimizing
sample treatment prior to analysis using MS focused on the
first week of lactation to the third month of lactation [12].
The range of metabolites contained in BM means that
no single analytic technique is capable of resolving the en-
tire BM metabolome. We designed an analytical strategy to
allow us to select the most appropriate analytical platforms
to resolve as many BM metabolites as possible. Analysis of
nonpolar metabolites in BM is essential. Lipids are one of
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the major energy sources in BM, contributing 40–55% of the
total energy of BM [27], and are essential for neurodevelop-
ment [28]. Furthermore, short chain fatty acids (SCFA) are
not only an important source of energy [29], but their pres-
ence in BM is essential for maturation of the gastrointestinal
tract [30]. Among the polarmetabolites, many interesting and
important classes of molecules are present such as digestible
sugars, which represent a readily available energy source for
the infant and are necessary for healthy growth; furthermore,
HMO, notable for their absence in infant formula, contribute
to establishing a healthy intestinal microbiome. In fact one
of the most prominent changes observed in the time course
analysis of BM were the decreasing concentrations of HMO
over the study period.
In order to ensure our profiling techniques adequately
covered these metabolite groups we chose UPLC-MS for
lipidomic analysis, GC-MS for the analysis of volatile polar
compounds, particularly SCFA. 1H NMR allowed broad cov-
erage of compounds from aromatic to aliphatic compounds;
it also gave some idea of the content of major lipid classes.
We selected CE-MS for the detection of ionizable polar
compounds present in BM, particularly amino acids, for
which it was the best method of detection. Amino acids have
been demonstrated to be important cell signaling molecules,
imbalances in particular amino acids,which are analytes of in-
terest in infant nutrition studies, can lead to health problems,
and are important in conditions such as phenylketonuria, and
may exert other specific negative physiological effects [31,32].
1HNMR, LC-MS, and CE-MS involveminimal sample prepa-
ration compared to GC-MS and therefore are suitable for BM
compositional screening of larger sample cohorts. The LOD
for each of the different analytical platforms is well estab-
lished. In regard to NMR spectroscopy (for a 600MHz instru-
ment), the LOD is in the nanomolecular range (10−9), while
for MS, the LOD is in the range of 10−14 to 10−18 mol [33].
Each platform contributed a set of unique metabolites to
the overall global profile. There was some overlap in metabo-
lites identified by the different platforms, but insofar as this
allows corroboration of the data, this may be regarded as
a strength of the multiplatform analytical approach. Ulti-
mately, given the complexity of BM composition, we have
demonstrated that there is no single analytical platform ca-
pable of identifying all metabolites present in milk, and that
each platform confers advantages for some chemical classes
of molecule and deficiencies in others.
We conclude that a multiplatform approach maximizes
the number of metabolites that can be identified in BM.
Clearly, it is not often practical to use three or four separate
analytical platforms to characterize every sample and thus
careful consideration should be given to choice of platform.
We found that the platforms used to assess the polar
components of BM gave the most statistically robust results.
CE-MS was the least reproducible of all techniques in terms
of RSD, but uniquely profiled amino acids in detail. For
global profiling we would recommend at the very least that
the platforms used should be capable of identifying both
polar and nonpolar metabolites. If using a single platform for
analysis, 1H NMR has the advantage of being highly repro-
ducible and allowing coverage of a large range of metabolite
classes including amino acids, sugars (simple through to
complex HMO), lipid (SCFA), and metabolic intermediaries
(e.g. TCA cycle metabolites). Both 1H NMR and MS can be
employed in quantitative/semiquantitative analysis.
With regard to the two different sample treatment
extraction methods, Folch extraction and single phase
methanol/MTBE (50:50) extraction, the optimal method to
use will depend on the analytical platform and analytes of
interest. The Folch extraction is compatible with all the ana-
lytical platforms evaluated here, allowing a single extraction
technique to be employed, and is therefore valuable when uti-
lizing a multiplatform approach for screening BM. However,
Folch extraction duplicates the number of analyses needed
due to the splitting of polar and nonpolar phases, which
must be analyzed independently. Another disadvantage of
Folch extraction is that metabolites present in high concen-
trations do not necessarily partition exclusively into either
one of the phases, therefore metabolite quantification based
on this method can be unreliable for some compounds. This
could partially account for the relatively poor performance of
the Folch extracted UPLC-MS models in distinguishing tem-
poral changes inBMover the early lactation period. The single
step method is unsuitable for use with 1H NMR as nonpolar
metabolites are retained, which further obscure spectra due
to overlapping signals.
In terms of numbers of metabolites, the single phase
extraction followed by HPLC-MS analysis gives the best pro-
file but did not capture the HMO, amino acids, and sugars
as well as some of the other techniques. Moreover, many of
the metabolites identified via the LC-MS methods need con-
firmation since the available databases are not adequate for
absolute structural confirmation. 1H NMR analysis of the po-
lar BM fraction gave the best insight into HMO and provided
the most reproducible data in terms of stability of the analyt-
ical profile and capturing systematic compositional changes
over time.
Beyond simply establishing a list of metabolites present
in BM (although this is not unimportant), in order to answer
questions of biological relevance it is necessary to show
that the analytical platforms used can be employed to study
relative changes in these metabolites between different milk
samples. We used our analytical platforms to assess the
temporal change in BM composition [34] over the first 3
months of lactation. This revealed temporal alterations in
keeping with previous reports using established biochemical
assays of BM composition.
Specifically, our findings confirm a number of previous
reports in relation to the changes in BM composition over
time. For example, Ilcol et al. demonstrated that glycerophos-
phocholine concentrations significantly increase in concen-
tration from colostrum to mature milk [2], we find similarly.
Tocopherol was decreased over the first week of lactation, but
remained at constant concentrations after this; this is in agree-
ment with reports showing a decrease in-tocopherol in early
lactation [35]. We also confirm previous reports of decreasing
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concentrations of citrate [36] and HMO [37], and increases
in lactose [38], glutamine, and alanine [37] in mature milk.
Carlson et al. previously described changes in amino acid
concentrations during lactation [37], which also matched our
observations. Our data demonstrate that the analytical tech-
niques utilized have the power to elucidate temporal changes
in breast milk in great detail, and to identify changes in hith-
erto unknown BM metabolites. For example, glycylglycine, a
dipeptide, was detected in breast milk using CE-MS, which
has not to our knowledge been identified previously. This ap-
proach will provide a unique opportunity to understand how
BM is biologically tailored to support human development.
Our work has identified many metabolites present in
BM whose biological function has not been fully elucidated,
an important avenue of future research. A limitation of the
current study is that it focuses on the first three months of
lactation and thus changes which occur later on in lactation
need illumination. As well as this, this study was performed
on a relatively small cohort size and a larger cohort would
give greater confidence that results obtained are applicable to
the population in general.
The composition of BM is complex and subject to the
influence of many factors such as the time of day samples
are collected, the time during the feed at which the sample is
collected, time since the last feed and maternal diet. Ideally
these factors require standardization to increase confidence
in results obtained from future studies, however they are of-
ten difficult to control. Solely investigating BM composition
reduces the complexity of the true relationship between the
mother and the infant through BM composition. For exam-
ple, factors present in BM are altered during digestion, and
can take on new properties, including acting as antimicrobial
agents [39].
BM contains a number of enzymes, which not only aid
the digestion of milk, but also play important roles in gut
development. The gut of the human infant has little lipase
activity, relying on the presence of lipoprotein lipase and bile
salt stimulated lipase for digestion of the tri- and diacylglyc-
erols in BM [40]. The relative changes in lipase concentrations
in the BM over the course of lactation, is a possible cause
of altered lipid profile. As well as this, factors such as HMO
selectively encourage the growth of beneficial bacteria,
orchestrating the development of the infant microbiome,
important for the immune andmetabolic development of the
infant [41].
The change in BM composition over lactation is known
to reflect the infant’s needs, becoming more energy dense
over lactation, with increasing carbohydrate and lipid concen-
trations to provide for the infants increased energy require-
ments. Total protein is seen to decrease, probably due to the
decreasing concentration of factors such as immunoglobu-
lins secreted into BM [42]. This not only reflects the infants
decreased requirement for them, as their own immune sys-
tem becomes functional, but also reflects the increasing in-
ability of the infant gut to absorb proteins, as gut closure
occurs and the permeability of the gut to macromolecules
decreases over the first 3 days of life [43].
In summary, we have shown the complementarity of
various analytical technologies for characterizing BM com-
position and have identified their respective strengths and
limitations. This comprehensive coverage of themetabolome
should provide a baseline for further studies to promote
understanding of the impact of maternal characteristics,
environmental, and dietary factors on BM composition and
inform the consequences this may have for infants. It will
also assist in the fulfillment of the ethical imperative to
design and produce the best nutrient support possible for
babies without access to BM.
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